NovaBridge Biosciences (NBP) Stock Forecast
NBP analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $9.00 average of analyst targets
- Upside to target
- +614.3% from the latest close
- Next earnings
- —
- 52-week range
- $1.26 – $5.22
NBP analyst ratings
2 analystsNumber of analysts at each rating.
NBP price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NBP earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$0.91 | −$0.91 | −$0.91 | −$0.48 | −89.6% | 1 |
| Next fiscal year (2027) | −$0.63 | −$0.63 | −$0.63 | −$0.91 | +30.8% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NBP revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 2 |
NBP EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NBP EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current fiscal year (2026) | −$0.94 | −$0.94 | −$0.94 | −$0.94 | −$0.91 | −3.2% | 0 up · 0 down |
| Next fiscal year (2027) | −$1.06 | −$1.06 | −$1.06 | −$1.06 | −$0.63 | −40.6% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NBP earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NBP beat in 5 of 12.
What analysts expect from NBP
2 analysts cover NovaBridge Biosciences; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.00, 614.3% above the latest close of $1.26. Analysts expect earnings of −$0.91 per share for 2026, −89.6% from a year earlier. For 2027 the average estimate is −$0.63 per share. NovaBridge Biosciences beat the EPS estimate in 5 of the last 12 quarters.
Related: NBP income statement, NBP key metrics, NBP chart. See the NBP stock overview for the latest quote and news.
NBP forecast FAQ
What is NovaBridge Biosciences's price target?
The average analyst price target for NovaBridge Biosciences is $9.00, 614.3% above the latest close of $1.26.
Is NovaBridge Biosciences a buy, hold or sell?
Of 2 analysts covering NovaBridge Biosciences, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is NovaBridge Biosciences's EPS forecast?
Analysts forecast −$0.91 per share for 2026 (range −$0.91 to −$0.91); for 2027 the estimate is −$0.63.
Does NovaBridge Biosciences usually beat earnings estimates?
NovaBridge Biosciences reported EPS at or above the analyst estimate in 5 of the last 12 quarters.